Skip to main content
Premium Trial:

Request an Annual Quote

Microlin Prices Shares in Planned IPO at $6-$8

Premium

Startup Microlin Bio last week revealed that it is aiming to price shares in its planned initial public offering at between $6 and $8 apiece.

The company did not provide any details regarding the expected timing of the transaction.

As reported by Gene Silencing News, Microlin filed to go public in January, just months after it was founded. The company's focus is the development of microRNA drugs and diagnostics based on intellectual property exclusively licensed from Ohio State University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.